TrialThe Lancet. Infectious diseases2015

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Katrin Ramsauer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.